Old drugs, new tricks for triple-negative breast cancer
Mené en Chine sur 240 patientes atteintes d'un cancer métastatique du sein triplement négatif, cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de deux combinaisons, cisplatine-gemcitabine et paclitaxel-gemcitabine, pour un traitement de première ligne
In The Lancet Oncology, Xi-Chun Hu and colleagues report results of the CBCSG006 trial, which assessed the non-inferiority and possible superiority of a cisplatin plus gemcitabine regimen versus a paclitaxel plus gemcitabine regimen in patients with metastatic triple-negative breast cancer. Cancer therapeutics can generally be divided into so-called “smart” drugs and “dumb” drugs. The perfect smart cancer drug is tumour-specific, targeted, highly effective, and has little toxicity, whereas cytotoxic chemotherapeutics are generally the representative dumb drugs.
The Lancet Oncology , commentaire, 2014